{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:05:52Z","timestamp":1790996752519,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":1054,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13311-020-00894-7","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T11:04:53Z","timestamp":1596539093000},"page":"1366-1377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Therapy of Parkinson's Disease Subtypes"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9236-9328","authenticated-orcid":false,"given":"Connie","family":"Marras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Titova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago A.","family":"Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1007\/s13311-020-00894-7_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1176\/jnp.14.2.223","article-title":"An essay on the shaking palsy. 1817","volume":"14","author":"Parkinson","year":"2002","journal-title":"The Journal of neuropsychiatry and clinical neurosciences."},{"issue":"S1","key":"10.1007\/s13311-020-00894-7_bib2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.870040502","article-title":"The history of parkinsonism","volume":"4","author":"Fahn","year":"1989","journal-title":"Movement Disorders."},{"issue":"6","key":"10.1007\/s13311-020-00894-7_bib3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/archneur.65.6.705","article-title":"There is no Parkinson disease","volume":"65","author":"Weiner","year":"2008","journal-title":"Archives of neurology."},{"issue":"10","key":"10.1007\/s13311-020-00894-7_bib4","first-page":"1529","article-title":"Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort","volume":"40","author":"Jankovic","year":"1990","journal-title":"The Parkinson Study Group. Neurology."},{"issue":"4","key":"10.1007\/s13311-020-00894-7_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1212\/WNL.35.4.522","article-title":"The heterogeneity of Parkinson's disease: clinical and prognostic implications","volume":"35","author":"Zetusky","year":"1985","journal-title":"Neurology."},{"issue":"2","key":"10.1007\/s13311-020-00894-7_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1212\/WNL.44.2.266","article-title":"Olfactory function in Parkinson's disease subtypes","volume":"44","author":"Stern","year":"1994","journal-title":"Neurology."},{"issue":"9","key":"10.1007\/s13311-020-00894-7_bib7","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/mds.20061","article-title":"Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson's disease","volume":"19","author":"Korchounov","year":"2004","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00894-7_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-7091-6360-3_1","article-title":"Post mortem studies in Parkinson's disease\u2013is it possible to detect brain areas for specific symptoms?","volume":"56","author":"Jellinger","year":"1999","journal-title":"Journal of Neural Transmission Supplementum."},{"issue":"9","key":"10.1007\/s13311-020-00894-7_bib9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1212\/WNL.39.9.1187","article-title":"Effect of age at onset on progression and mortality in Parkinson's disease","volume":"39","author":"Diamond","year":"1989","journal-title":"Neurology."},{"issue":"15","key":"10.1007\/s13311-020-00894-7_bib10","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0000000000002461","article-title":"Age at onset and Parkinson disease phenotype","volume":"86","author":"Pagano","year":"2016","journal-title":"Neurology."},{"issue":"3","key":"10.1007\/s13311-020-00894-7_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson's Disease in Women and Men: What's the Difference?","volume":"9","author":"Cerri","year":"2019","journal-title":"J Parkinsons Dis."},{"issue":"8","key":"10.1007\/s13311-020-00894-7_bib12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/jnnp.2006.103788","article-title":"Gender differences in Parkinson's disease","volume":"78","author":"Haaxma","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"8","key":"10.1007\/s13311-020-00894-7_bib13","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/mds.26510","article-title":"Nonmotor features of Parkinson's disease subtypes","volume":"31","author":"Marras","year":"2016","journal-title":"Mov Disord."},{"issue":"7","key":"10.1007\/s13311-020-00894-7_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/jnnp.2010.213652","article-title":"Depression and anxiety related subtypes in Parkinson's disease","volume":"82","author":"Brown","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"3","key":"10.1007\/s13311-020-00894-7_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.parkreldis.2009.11.002","article-title":"Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics","volume":"16","author":"Sollinger","year":"2010","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1007\/s13311-020-00894-7_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.parkreldis.2018.05.009","article-title":"Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene","volume":"55","author":"Thaler","year":"2018","journal-title":"Parkinsonism Relat Disord."},{"issue":"7","key":"10.1007\/s13311-020-00894-7_bib17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/jnnp-2017-317348","article-title":"Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study","volume":"89","author":"Malek","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"4","key":"10.1007\/s13311-020-00894-7_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.0b013e318227042d","article-title":"Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers","volume":"77","author":"Marras","year":"2011","journal-title":"Neurology."},{"issue":"8","key":"10.1007\/s13311-020-00894-7_bib19","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/mds.26614","article-title":"Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease","volume":"31","author":"Marras","year":"2016","journal-title":"Mov Disord."},{"issue":"14","key":"10.1007\/s13311-020-00894-7_bib20","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/mds.25647","article-title":"Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations","volume":"28","author":"Alcalay","year":"2013","journal-title":"Mov Disord."},{"issue":"1","key":"10.1007\/s13311-020-00894-7_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/1531-8257(199901)14:1<10::AID-MDS1005>3.0.CO;2-4","article-title":"A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes","volume":"14","author":"Graham","year":"1999","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00894-7_bib22","doi-asserted-by":"crossref","unstructured":"Mestre TA, Eberly S, Tanner C, Grimes D, Lang AE, Oakes D, et al. Reproducibility of data-driven Parkinson's disease subtypes for clinical research. Parkinsonism Relat Disord. 2018.","DOI":"10.1016\/j.parkreldis.2018.07.009"},{"issue":"5","key":"10.1007\/s13311-020-00894-7_bib23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.parkreldis.2014.02.013","article-title":"Comparing clinical features of young onset, middle onset and late onset Parkinson's disease","volume":"20","author":"Mehanna","year":"2014","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"10.1007\/s13311-020-00894-7_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/mds.23469","article-title":"The motor phenotype of Parkinson's disease in relation to age at onset","volume":"26","author":"Wickremaratchi","year":"2011","journal-title":"Mov Disord."},{"issue":"4","key":"10.1007\/s13311-020-00894-7_bib25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-0404.1994.tb01676.x","article-title":"Old-onset Parkinson's disease compared with young-onset disease: clinical differences and similarities","volume":"89","author":"Friedman","year":"1994","journal-title":"Acta Neurol Scand."},{"issue":"4","key":"10.1007\/s13311-020-00894-7_bib26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archneur.60.4.529","article-title":"Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset","volume":"60","author":"Diederich","year":"2003","journal-title":"Archives of neurology."},{"issue":"12","key":"10.1007\/s13311-020-00894-7_bib27","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1212\/WNL.38.12.1841","article-title":"Risk factors for progression in Parkinson's disease","volume":"38","author":"Goetz","year":"1988","journal-title":"Neurology."},{"issue":"4","key":"10.1007\/s13311-020-00894-7_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1468-1331.2008.02514.x","article-title":"The effect of onset age on the clinical features of Parkinson's disease","volume":"16","author":"Wickremaratchi","year":"2009","journal-title":"European Journal of Neurology."},{"issue":"3","key":"10.1007\/s13311-020-00894-7_bib29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mds.870120303","article-title":"Clinical and pharmacological differences in early- versus late-onset Parkinson's disease","volume":"12","author":"Gomez Arevalo","year":"1997","journal-title":"Mov Disord."},{"issue":"1","key":"10.1007\/s13311-020-00894-7_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNF.0b013e31823dec73","article-title":"What factors influence motor complications in Parkinson disease?: a 10-year prospective study","volume":"35","author":"Garcia-Ruiz","year":"2012","journal-title":"Clin Neuropharmacol."},{"issue":"4","key":"10.1007\/s13311-020-00894-7_bib31","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamaneurol.2018.4377","article-title":"Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease","volume":"76","author":"De Pablo-Fernandez","year":"2019","journal-title":"JAMA Neurol."},{"issue":"20","key":"10.1007\/s13311-020-00894-7_bib32","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"The New England journal of medicine."},{"key":"10.1007\/s13311-020-00894-7_bib33","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1016\/j.wneu.2018.03.021","article-title":"Risk Factors for Postoperative Delirium After Deep Brain Stimulation Surgery for Parkinson Disease","volume":"114","author":"Tanaka","year":"2018","journal-title":"World Neurosurg."},{"issue":"1","key":"10.1007\/s13311-020-00894-7_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/mds.27222","article-title":"Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age","volume":"33","author":"Dafsari","year":"2018","journal-title":"Mov Disord."},{"issue":"4","key":"10.1007\/s13311-020-00894-7_bib35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bpa.12182","article-title":"Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias","volume":"25","author":"Howlett","year":"2015","journal-title":"Brain Pathol."},{"issue":"Suppl 1","key":"10.1007\/s13311-020-00894-7_bib36","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1016\/j.parkreldis.2015.09.019","article-title":"The contribution of white matter lesions (WML) to Parkinson's disease cognitive impairment symptoms: A critical review of the literature","volume":"22","author":"Vesely","year":"2016","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"10.1007\/s13311-020-00894-7_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00702-015-1470-9","article-title":"The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature","volume":"123","author":"Vesely","year":"2016","journal-title":"J Neural Transm (Vienna)."},{"issue":"4","key":"10.1007\/s13311-020-00894-7_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00002826-198908000-00006","article-title":"Tremors in early Parkinson's disease","volume":"12","author":"Koller","year":"1989","journal-title":"Clin Neuropharmacol."},{"issue":"1","key":"10.1007\/s13311-020-00894-7_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/mds.21793","article-title":"Factors predicting response to dopaminergic treatment for resting tremor of Parkinson's disease","volume":"23","author":"Sung","year":"2008","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00894-7_bib40","doi-asserted-by":"crossref","unstructured":"Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003(2):CD003735.","DOI":"10.1002\/14651858.CD003735"},{"issue":"6","key":"10.1007\/s13311-020-00894-7_bib41","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1212\/WNL.49.6.1587","article-title":"Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration","volume":"49","author":"Bonuccelli","year":"1997","journal-title":"Neurology."},{"issue":"8","key":"10.1007\/s13311-020-00894-7_bib42","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archneurol.2011.160","article-title":"Deep brain stimulation in benign tremulous parkinsonism","volume":"68","author":"Savica","year":"2011","journal-title":"Archives of neurology."},{"issue":"15","key":"10.1007\/s13311-020-00894-7_bib43","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results","volume":"23","author":"Goetz","year":"2008","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00894-7_bib44","unstructured":"Fahn S, Elton R, Committee. MotUD. The Unified Parkinson's Disease Rating Scale. In: Fahn S MC, Calne DB, Goldstein M, editor. Recent Developments in Parkinson's Disease. 2. Florham Park: Macmillan Health Care Information; 1987. p. 153-63."},{"issue":"15","key":"10.1007\/s13311-020-00894-7_bib45","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1212\/WNL.0000000000003213","article-title":"Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study","volume":"87","author":"Bjornestad","year":"2016","journal-title":"Neurology."},{"issue":"24","key":"10.1007\/s13311-020-00894-7_bib46","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1212\/WNL.0000000000002670","article-title":"Quality improvement in neurology: Parkinson disease update quality measurement set: Executive summary","volume":"86","author":"Factor","year":"2016","journal-title":"Neurology."},{"issue":"4","key":"10.1007\/s13311-020-00894-7_bib47","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.24374","article-title":"Differential effects of deep brain stimulation target on motor subtypes in Parkinson's disease","volume":"77","author":"Katz","year":"2015","journal-title":"Annals of neurology."},{"key":"10.1007\/s13311-020-00894-7_bib48","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.parkreldis.2016.04.027","article-title":"How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?","volume":"28","author":"Simuni","year":"2016","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1007\/s13311-020-00894-7_bib49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.parkreldis.2017.07.018","article-title":"Motor subtype changes in early Parkinson's disease","volume":"43","author":"Eisinger","year":"2017","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1007\/s13311-020-00894-7_bib50","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.parkreldis.2019.06.017","article-title":"Motor phenotype classification in moderate to advanced PD in BioFIND study","volume":"65","author":"Luo","year":"2019","journal-title":"Parkinsonism Relat Disord."},{"issue":"Pt 11","key":"10.1007\/s13311-020-00894-7_bib51","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/brain\/awp234","article-title":"A clinico-pathological study of subtypes in Parkinson's disease","volume":"132","author":"Selikhova","year":"2009","journal-title":"Brain : a journal of neurology."},{"issue":"8","key":"10.1007\/s13311-020-00894-7_bib52","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/mds.27027","article-title":"Personalized medicine in Parkinson's disease: Time to be precise","volume":"32","author":"Titova","year":"2017","journal-title":"Mov Disord."},{"issue":"7","key":"10.1007\/s13311-020-00894-7_bib53","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat Rev Neurosci."},{"key":"10.1007\/s13311-020-00894-7_bib54","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/bs.irn.2017.05.017","article-title":"Nonmotor Parkinson's and Future Directions","volume":"134","author":"Titova","year":"2017","journal-title":"Int Rev Neurobiol."},{"issue":"2","key":"10.1007\/s13311-020-00894-7_bib55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord."},{"issue":"Suppl 1","key":"10.1007\/s13311-020-00894-7_bib56","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.parkreldis.2015.09.027","article-title":"Non motor subtypes and Parkinson's disease","volume":"22","author":"Sauerbier","year":"2016","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"10.1007\/s13311-020-00894-7_bib57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat Rev Neurol."},{"issue":"Pt 3","key":"10.1007\/s13311-020-00894-7_bib58","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/brain\/awu369","article-title":"Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET","volume":"138","author":"Gjerloff","year":"2015","journal-title":"Brain : a journal of neurology."},{"issue":"8","key":"10.1007\/s13311-020-00894-7_bib59","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1212\/WNL.0000000000003633","article-title":"Decreased intestinal acetylcholinesterase in early Parkinson disease: An (11)C-donepezil PET study","volume":"88","author":"Fedorova","year":"2017","journal-title":"Neurology."},{"issue":"11","key":"10.1007\/s13311-020-00894-7_bib60","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/brain\/awq268","article-title":"Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction","volume":"133","author":"Pavese","year":"2010","journal-title":"Brain : a journal of neurology."},{"key":"10.1007\/s13311-020-00894-7_bib61","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.nicl.2018.03.001","article-title":"Serotonergic dysregulation is linked to sleep problems in Parkinson's disease","volume":"18","author":"Wilson","year":"2018","journal-title":"Neuroimage Clin."},{"issue":"1","key":"10.1007\/s13311-020-00894-7_bib62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12868-019-0537-1","article-title":"Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson's disease","volume":"20","author":"Niccolini","year":"2019","journal-title":"BMC neuroscience."},{"issue":"8","key":"10.1007\/s13311-020-00894-7_bib63","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00702-017-1823-7","article-title":"The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies","volume":"125","author":"Pagano","year":"2018","journal-title":"J Neural Transm (Vienna)."},{"issue":"14","key":"10.1007\/s13311-020-00894-7_bib64","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/mds.26048","article-title":"Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement","volume":"29","author":"Espay","year":"2014","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00894-7_bib65","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41531-017-0017-1","article-title":"Imaging Parkinson's disease below the neck","volume":"3","author":"Borghammer","year":"2017","journal-title":"NPJ Parkinsons Dis."},{"issue":"2","key":"10.1007\/s13311-020-00894-7_bib66","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/brain\/awx348","article-title":"Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study","volume":"141","author":"Sommerauer","year":"2018","journal-title":"Brain : a journal of neurology."},{"issue":"7","key":"10.1007\/s13311-020-00894-7_bib67","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1113\/jphysiol.2014.271304","article-title":"Cholinergic involvement in control of REM sleep paralysis","volume":"592","author":"Torontali","year":"2014","journal-title":"The Journal of physiology."},{"key":"10.1007\/s13311-020-00894-7_bib68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/bs.irn.2017.05.030","article-title":"Nonmotor Signs in Genetic Forms of Parkinson's Disease","volume":"133","author":"Kasten","year":"2017","journal-title":"Int Rev Neurobiol."},{"issue":"5","key":"10.1007\/s13311-020-00894-7_bib69","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ana.24781","article-title":"Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's","volume":"80","author":"Liu","year":"2016","journal-title":"Annals of neurology."},{"issue":"1","key":"10.1007\/s13311-020-00894-7_bib70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.26359","article-title":"GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease","volume":"31","author":"Mata","year":"2016","journal-title":"Mov Disord."},{"issue":"9","key":"10.1007\/s13311-020-00894-7_bib71","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1073\/pnas.1300822110","article-title":"Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease","volume":"110","author":"Schapira","year":"2013","journal-title":"Proceedings of the National Academy of Sciences."},{"issue":"12","key":"10.1007\/s13311-020-00894-7_bib72","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.wnl.0000276989.17578.02","article-title":"Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease","volume":"69","author":"Clark","year":"2007","journal-title":"Neurology."},{"issue":"17","key":"10.1007\/s13311-020-00894-7_bib73","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"The New England journal of medicine."},{"issue":"24","key":"10.1007\/s13311-020-00894-7_bib74","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1212\/01.wnl.0000304039.11891.29","article-title":"Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset","volume":"70","author":"Gan-Or","year":"2008","journal-title":"Neurology."},{"issue":"3","key":"10.1007\/s13311-020-00894-7_bib75","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.26071","article-title":"GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study","volume":"30","author":"Brockmann","year":"2015","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00894-7_bib76","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jns.2016.08.059","article-title":"Neuropsychiatric characteristics of GBA-associated Parkinson disease","volume":"370","author":"Swan","year":"2016","journal-title":"J Neurol Sci."},{"issue":"18","key":"10.1007\/s13311-020-00894-7_bib77","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e318253d54b","article-title":"Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study","volume":"78","author":"Alcalay","year":"2012","journal-title":"Neurology."},{"issue":"Pt 2","key":"10.1007\/s13311-020-00894-7_bib78","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/brain\/aws318","article-title":"Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort","volume":"136","author":"Winder-Rhodes","year":"2013","journal-title":"Brain : a journal of neurology."},{"issue":"10","key":"10.1007\/s13311-020-00894-7_bib79","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","article-title":"Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease","volume":"73","author":"Davis","year":"2016","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1007\/s13311-020-00894-7_bib80","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ana.24777","article-title":"Survival and dementia in GBA-associated Parkinson's disease: The mutation matters","volume":"80","author":"Cilia","year":"2016","journal-title":"Annals of neurology."},{"issue":"2","key":"10.1007\/s13311-020-00894-7_bib81","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat Rev Neurol."},{"issue":"7","key":"10.1007\/s13311-020-00894-7_bib82","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-020-00894-7_bib83","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMc055540","article-title":"LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs","volume":"354","author":"Lesage","year":"2006","journal-title":"The New England journal of medicine"},{"key":"10.1007\/s13311-020-00894-7_bib84","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMc055509","article-title":"LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews","volume":"354","author":"Ozelius","year":"2006","journal-title":"The New England journal of medicine"},{"issue":"12","key":"10.1007\/s13311-020-00894-7_bib85","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/mds.25587","article-title":"Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation","volume":"28","author":"Mirelman","year":"2013","journal-title":"Mov Disord."},{"issue":"7","key":"10.1007\/s13311-020-00894-7_bib86","doi-asserted-by":"crossref","first-page":"e0132368","DOI":"10.1371\/journal.pone.0132368","article-title":"Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers","volume":"10","author":"Pont-Sunyer","year":"2015","journal-title":"PloS one."},{"issue":"3","key":"10.1007\/s13311-020-00894-7_bib87","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2017.4019","article-title":"Progression in the LRRK2-Asssociated Parkinson Disease Population","volume":"75","author":"Saunders-Pullman","year":"2018","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1007\/s13311-020-00894-7_bib88","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/mds.27490","article-title":"Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes","volume":"33","author":"Thaler","year":"2018","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00894-7_bib89","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12868-016-0240-4","article-title":"Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers","volume":"17","author":"Sayad","year":"2016","journal-title":"BMC neuroscience."},{"issue":"11","key":"10.1007\/s13311-020-00894-7_bib90","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.parkreldis.2013.07.005","article-title":"The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease","volume":"19","author":"Greenbaum","year":"2013","journal-title":"Parkinsonism Relat Disord."},{"issue":"2","key":"10.1007\/s13311-020-00894-7_bib91","doi-asserted-by":"crossref","first-page":"e187800","DOI":"10.1001\/jamanetworkopen.2018.7800","article-title":"Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis","volume":"2","author":"Artusi","year":"2019","journal-title":"JAMA Netw Open."},{"issue":"3","key":"10.1007\/s13311-020-00894-7_bib92","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00415-020-09705-7","article-title":"Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease","volume":"267","author":"Schneider","year":"2020","journal-title":"J Neurol."},{"key":"10.1007\/s13311-020-00894-7_bib93","doi-asserted-by":"crossref","unstructured":"Mullin S, Smith L, Lee K, D'Souza G, Woodgate P, Elflein J, et al. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol. 2020.","DOI":"10.1001\/jamaneurol.2019.4611"},{"key":"10.1007\/s13311-020-00894-7_bib94","doi-asserted-by":"crossref","unstructured":"Peterschmitt M, Gasser T, Isaacson S. Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a GBA mutation. Mol Genet Metabol Rep. 2019;126.","DOI":"10.1016\/j.ymgme.2018.12.298"},{"key":"10.1007\/s13311-020-00894-7_bib95","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.parkreldis.2018.10.025","article-title":"New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics","volume":"59","author":"Sardi","year":"2019","journal-title":"Parkinsonism Relat Disord."},{"issue":"28","key":"10.1007\/s13311-020-00894-7_bib96","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1523\/JNEUROSCI.3642-15.2016","article-title":"G2019S-LRRK2 Expression Augments alpha-Synuclein Sequestration into Inclusions in Neurons","volume":"36","author":"Volpicelli-Daley","year":"2016","journal-title":"J Neurosci."},{"key":"10.1007\/s13311-020-00894-7_bib97","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 Antisense Oligonucleotides Ameliorate alpha-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol Ther Nucleic Acids."},{"key":"10.1007\/s13311-020-00894-7_bib98","unstructured":"Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson's Disease 2019 [Available from: https:\/\/www.biospace.com\/article\/releases\/denali-therapeutics-announces-broad-pipeline-progress-including-positive-results-from-its-lrrk2-program-for-parkinson-s-disease\/] Accessed 30 July 2020"},{"issue":"12","key":"10.1007\/s13311-020-00894-7_bib99","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol."},{"issue":"Pt 9","key":"10.1007\/s13311-020-00894-7_bib100","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/brain\/awv179","article-title":"Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations","volume":"138","author":"Alcalay","year":"2015","journal-title":"Brain : a journal of neurology."},{"issue":"451","key":"10.1007\/s13311-020-00894-7_bib101","doi-asserted-by":"crossref","first-page":"eaar5429","DOI":"10.1126\/scitranslmed.aar5429","article-title":"LRRK2 activation in idiopathic Parkinson's disease","volume":"10","author":"Di Maio","year":"2018","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1007\/s13311-020-00894-7_bib102","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","article-title":"Developing and validating Parkinson's disease subtypes and their motor and cognitive progression","volume":"89","author":"Lawton","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"7","key":"10.1007\/s13311-020-00894-7_bib103","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/brain\/awx118","article-title":"Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression","volume":"140","author":"Fereshtehnejad","year":"2017","journal-title":"Brain : a journal of neurology."},{"issue":"2","key":"10.1007\/s13311-020-00894-7_bib104","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/mds.27888","article-title":"Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort","volume":"35","author":"Lawton","year":"2020","journal-title":"Mov Disord."},{"issue":"21","key":"10.1007\/s13311-020-00894-7_bib105","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJM200005253422103","article-title":"Association between early-onset Parkinson's disease and mutations in the parkin gene","volume":"342","author":"Lucking","year":"2000","journal-title":"The New England journal of medicine."},{"issue":"s1","key":"10.1007\/s13311-020-00894-7_bib106","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.3233\/JPD-181465","article-title":"Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence","volume":"8","author":"Espay","year":"2018","journal-title":"J Parkinsons Dis."},{"issue":"5","key":"10.1007\/s13311-020-00894-7_bib107","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mgg3.151","article-title":"Novel recruitment strategy to enrich for LRRK2 mutation carriers","volume":"3","author":"Foroud","year":"2015","journal-title":"Mol Genet Genomic Med."},{"issue":"2","key":"10.1007\/s13311-020-00894-7_bib108","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10897-014-9756-x","article-title":"Interest in genetic testing in Ashkenazi Jewish Parkinson's disease patients and their unaffected relatives","volume":"24","author":"Gupte","year":"2015","journal-title":"J Genet Couns."},{"issue":"3","key":"10.1007\/s13311-020-00894-7_bib109","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/cpt.1634","article-title":"Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs","volume":"107","author":"Ahamadi","year":"2020","journal-title":"Clin Pharmacol Ther."},{"issue":"6","key":"10.1007\/s13311-020-00894-7_bib110","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical progression in Parkinson disease and the neurobiology of axons","volume":"67","author":"Cheng","year":"2010","journal-title":"Annals of neurology."},{"issue":"10","key":"10.1007\/s13311-020-00894-7_bib111","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/mds.27059","article-title":"Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry","volume":"32","author":"Lee","year":"2017","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00894-7_bib112","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1741-7015-6-32","article-title":"The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study","volume":"6","author":"Latourelle","year":"2008","journal-title":"BMC Med."},{"issue":"2","key":"10.1007\/s13311-020-00894-7_bib113","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/gim.2012.107","article-title":"Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling","volume":"15","author":"Rana","year":"2013","journal-title":"Genet Med."},{"issue":"6","key":"10.1007\/s13311-020-00894-7_bib114","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","article-title":"Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers","volume":"78","author":"Anheim","year":"2012","journal-title":"Neurology."},{"issue":"6","key":"10.1007\/s13311-020-00894-7_bib115","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(16)00060-0","article-title":"Challenges of modifying disease progression in prediagnostic Parkinson's disease","volume":"15","author":"Salat","year":"2016","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1007\/s13311-020-00894-7_bib116","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/mds.26989","article-title":"Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort","volume":"32","author":"Fereshtehnejad","year":"2017","journal-title":"Mov Disord."},{"issue":"1","key":"10.1007\/s13311-020-00894-7_bib117","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ejn.13476","article-title":"Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PR EDIGT score","volume":"45","author":"Schlossmacher","year":"2017","journal-title":"Eur J Neurosci."},{"issue":"8","key":"10.1007\/s13311-020-00894-7_bib118","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1474-4422(17)30122-9","article-title":"Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts","volume":"16","author":"Liu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-020-00894-7_bib119","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/bs.irn.2017.02.016","article-title":"The Nonmotor Features of Parkinson's Disease","volume":"132","author":"Titova","year":"2017","journal-title":"Int Rev Neurobiol."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00894-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-020-00894-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00894-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:57:01Z","timestamp":1761807421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923012461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1878747923012461"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-00894-7","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy of Parkinson's Disease Subtypes","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-00894-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}